IMNM Q4 2025 Earnings — Immunome, Inc. Revenue & Financial Results | Market Cap Arena

IMNMImmunome, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0-100.0% YoY

Gross Profit

$43M

Operating Income

-$73M

Net Income

-$70M

EPS (Diluted)

$-0.76

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$48M

Free Cash Flow

-$52M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$683M

Total Liabilities

$49M

Stockholders' Equity

$634M

Cash & Equivalents

$653M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$3M	-100.0%
Gross Profit	$43M	$3M	+1469.5%
Operating Income	-$73M	-$83M	+12.2%
Net Income	-$70M	-$80M	+12.9%